Insider Trading May 6, 2026 08:22 PM

FIGS CFO Executes Share Sale Under Pre-Arranged Trading Plan

Sarah Oughtred liquidates approximately $338,237 in Class A Common Stock to meet tax obligations following RSU vesting.

By Priya Menon FIGS

Sarah Oughtred, the Chief Financial Officer of FIGS, Inc. (NYSE:FIGS), completed a sale of 23,597 shares of the company’s Class A Common Stock on May 4, 2026. The transaction, which comprised several individual trades, resulted in a total value of roughly $338,237. These sales were conducted at a weighted average price of $14.3339 per share, with individual transaction prices fluctuating between $14.160 and $14.344 per share.The divestment was not an opportunistic market trade but rather a structured execution under a 10b5-1 trading plan that had been established on August 13, 2024. According to regulatory filings, the purpose of these sales was to cover tax liabilities that arose from the settlement and vesting of restricted stock units (RSUs). Following this activity, Ms. Oughtred maintains a direct holding of 1,129,791 shares of FIGS Class A Common Stock, a figure that includes 953,028 restricted stock units which represent a contingent right to receive one share of Class A Common Stock each.This insider activity occurs amidst a period of significant price movement for the company. Over the preceding year, FIGS shares have seen a surge of nearly 197%, with the stock recently trading at $14.50 and maintaining a market capitalization of $2.42 billion. While current market data shows the stock at $14.50, analysis suggests it may still be undervalued relative to its calculated Fair Value.

FIGS CFO Executes Share Sale Under Pre-Arranged Trading Plan
FIGS

Key Points

  • The CFO's share sale was a pre-planned transaction for tax purposes related to RSU vesting.
  • FIGS reported its strongest quarterly revenue growth in four years at 33%.
  • Analysts have responded to improved KPIs with price target increases and rating upgrades.

Executive Transaction Details

On May 4, 2026, FIGS, Inc. Chief Financial Officer Sarah Oughtred executed a sale of 23,597 shares of Class A Common Stock. The total proceeds from these transactions were approximately $338,237. The selling process involved multiple trades at varying price points, specifically ranging from $14.160 to $14.344 per share, leading to a weighted average execution price of $14.3339.

The transaction was carried out via a pre-arranged 10b5-1 trading plan, a mechanism set up on August 13, 2024. The primary driver for this specific sale was the requirement to cover tax obligations stemming from the vesting and settlement of restricted stock units (RSUs). Despite this sale, Ms. Oughtred retains a substantial direct interest in the company, holding 1,129,791 shares of Class A Common Stock, which includes 953,028 RSUs that provide the contingent right to receive one share of common stock per unit.


Recent Financial Performance and Market Momentum

The insider transaction follows a period of robust financial growth for FIGS, Inc. The company recently reported its fourth-quarter results for fiscal 2025, which featured a 33% increase in revenue. This represents the strongest growth rate the company has seen in four years. This upward trajectory was supported by strength across all categories and geographic regions. Key metrics driving this performance included an increase of 140,000 active customers and an 8.6% year-over-year rise in average order value.

Analyst Perspectives

The company's recent operational improvements have prompted several shifts in analyst sentiment:

  • Barclays: Upgraded the stock from Equalweight to Overweight, citing a return to the core growth thesis.
  • Goldman Sachs: Upgraded the rating from Sell to Neutral and increased the price target from $7.50 up to $14.00, noting improvements in key performance indicators.
  • Telsey Advisory Group: Maintained a Market Perform rating but raised the price target from $15 to $17, based on a 28.5x multiple of their two-year forward EBITDA estimate of $100 million.
  • KeyBanc: Raised its price target from $17.00 to $19.00, pointing toward momentum in international markets and active customer growth.

These adjustments collectively suggest a level of optimism among analysts regarding the company's disciplined expense management and recent business momentum.


Key Points

  • Structured Liquidity: The sale by the CFO was part of a pre-arranged 10b5-1 plan to address tax obligations, rather than a spontaneous market move. This impacts the consumer discretionary sector by highlighting how executive compensation structures interact with liquidity needs.
  • Strong Revenue Growth: FIGS reported its highest growth rate in four years with a 33% revenue increase in Q4 fiscal 2025, driven by customer acquisition and higher order values. This demonstrates momentum within the retail and apparel sectors.
  • Positive Analyst Revisions: Multiple financial institutions have raised price targets or upgraded ratings, reflecting confidence in the company's performance indicators and international expansion.

Risks and Uncertainties

  • Valuation Sensitivity: While some analysis suggests the stock is undervalued, the significant 197% surge over the last year implies that much of the growth may already be priced in, which can lead to volatility in the consumer goods market.
  • Growth Sustainability: Although revenue grew by 33%, the company's ability to maintain this momentum across all regions and categories remains a central factor for long-term valuation.

Risks

  • Potential market volatility following a nearly 197% share price surge over the past year.
  • The necessity of maintaining high customer acquisition and order value growth to support current valuations.

More from Insider Trading

Magnetar-Affiliated Funds Liquidate $124.96 Million in CoreWeave Class A Shares May 6, 2026 Magnetar Financial Reduces CoreWeave Position via $53.5 Million Share Sale May 6, 2026 Magnetar Investment Vehicles Execute $147 Million Divestment of CoreWeave Shares May 6, 2026 RB Global Inc. Executive Executes Common Share Sale Amid Recent Earnings Beat May 6, 2026 MapLight Therapeutics CFO Executes $1.02 Million Stock Sale Amid Clinical Milestones May 6, 2026